Related Experiment Videos
Valproate monotherapy in children
1Division of Neurosciences, Children's Mercy Hospital, Kansas City, Missouri 64108.
Insights
Pediatric epilepsy patients often benefit from antiepileptic drug monotherapy, improving seizure control and reducing side effects. Valproate monotherapy is a preferred treatment for primary generalized seizures in children.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Seizures are more prevalent in children than adults.
- Most pediatric epilepsies are manageable with single antiepileptic drugs (AEDs).
Purpose of the Study:
- To evaluate the benefits of antiepileptic drug monotherapy versus polytherapy in pediatric epilepsy.
- To highlight valproate as a preferred monotherapy for primary generalized seizures in children.
Main Methods:
- Review of current treatment guidelines and clinical evidence for pediatric epilepsy management.
- Analysis of comparative efficacy and safety data for monotherapy versus polytherapy.
Main Results:
- Over half of pediatric epilepsy patients on polytherapy experience improved seizure control and reduced side effects with monotherapy.
- Valproate is a recommended first-line treatment for primary generalized seizures, with a lower risk of fatal hepatotoxicity in monotherapy (1:10,000) compared to polytherapy.
Conclusions:
- Monotherapy is recommended for pediatric epilepsy when feasible, offering better seizure control and fewer adverse effects.
- Valproate monotherapy presents advantages including avoidance of drug interactions, lower cost, and preserved cognitive function in children.
Abstract:
Seizures are more common in children than in adults. Since most pediatric epilepsies can be controlled with a single antiepileptic drug, children with epilepsy should receive monotherapy when possible or switch from polytherapy to monotherapy. More than half of the epileptic patients receiving multiple antiepileptic drugs will have better seizure control as well as fewer side effects with monotherapy. Most of the pediatric epilepsies occur as primary generalized seizures, for which valproate is a preferred drug. Children can begin to receive valproate treatment in a dosage of 20 to 30 mg/kg per day in two or three divided doses. After several days, plasma levels may be useful in adjusting the dosage. The major adverse effect of valproate in children is fatal hepatotoxicity. The risk of this complication is considerably lower with valproate monotherapy (one per 10,000 patients) than with polytherapy. Other advantages of valproate monotherapy, compared with polytherapy, include the avoidance of drug interactions, lower cost, and reduced potential for impaired cognitive function, which is particularly important in children.